BLUENERGIES LTD (BLU.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:BLU - CA0959221007 - Common Stock
BLU.CA Key Statistics, Chart & Performance
The current stock price of BLU.CA is 1 CAD. In the past month the price decreased by -15.97%.
BLU.CA Latest News, Press Relases and Analysis
BLU.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 450.28M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 368.56M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 175.67M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 127.62M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.13 | 52.92M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 33.48M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 31.54M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 22.50M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 15.64M | ||
| MPH.CA | MEDICURE INC | N/A | 12.95M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.29M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 7.61M |
Related stock screener links
About BLU.CA
Company Profile
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Company Info
BLUENERGIES LTD
275 Armand-Frappier Blvd
Laval QUEBEC H7V 4A7 CA
CEO: Roberto Bellini
Employees: 74
Phone: 14506804500.0
BLUENERGIES LTD / BLU.CA FAQ
Can you describe the business of BLUENERGIES LTD?
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Can you provide the latest stock price for BLUENERGIES LTD?
The current stock price of BLU.CA is 1 CAD. The price increased by 11.11% in the last trading session.
What is the dividend status of BLUENERGIES LTD?
BLU.CA does not pay a dividend.
What is the ChartMill rating of BLUENERGIES LTD stock?
BLU.CA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists BLU stock?
BLU.CA stock is listed on the Toronto Stock Exchange exchange.
What is the next earnings date for BLU stock?
BLUENERGIES LTD (BLU.CA) will report earnings on 2022-02-24.
BLU.CA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BLU.CA.
BLU.CA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |